Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

ABSTRACT:

Objective

Fibroblast growth factor 21 (FGF21) ameliorates steatohepatitis but is increased in humans with fatty liver, potentially due to compensatory mechanisms and/or FGF21 resistance. Further, animal models suggest that GH increases serum FGF21. Tesamorelin, a growth hormone releasing hormone agonist, reduces liver fat in HIV-infected individuals. The objectives of this study were to investigate changes in FGF21 during tesamorelin treatment, to elucide the interplay between FGF21, GH augmentation, and liver fat reduction in humans.

Methods

50 HIV-infected men and women with increased abdominal adiposity participated in this randomized, placebo-controlled trial of tesamorelin, 2mg vs. identical placebo daily for six months. Fasting laboratory measures, liver fat by ^1<

SUBMITTER: Braun LR 

PROVIDER: S-EPMC5705434 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature